Financial Partners Group Inc lowered its holdings in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,658 shares of the financial services provider’s stock after selling 562 shares during the period. iShares Nasdaq Biotechnology ETF makes up about 2.3% of Financial Partners Group Inc’s portfolio, making the stock its 15th largest holding. Financial Partners Group Inc owned approximately 0.07% of iShares Nasdaq Biotechnology ETF worth $6,589,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. AlphaMark Advisors LLC bought a new stake in shares of iShares Nasdaq Biotechnology ETF during the 3rd quarter worth approximately $27,000. JFS Wealth Advisors LLC lifted its stake in iShares Nasdaq Biotechnology ETF by 488.9% during the third quarter. JFS Wealth Advisors LLC now owns 265 shares of the financial services provider’s stock worth $36,000 after purchasing an additional 220 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new stake in shares of iShares Nasdaq Biotechnology ETF in the 2nd quarter valued at $41,000. Clear Harbor Asset Management LLC bought a new position in shares of iShares Nasdaq Biotechnology ETF in the 3rd quarter valued at $45,000. Finally, South State CORP. raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 32.8% during the 3rd quarter. South State CORP. now owns 332 shares of the financial services provider’s stock worth $45,000 after buying an additional 82 shares in the last quarter. 82.54% of the stock is owned by hedge funds and other institutional investors.
IBB stock traded up $0.44 during trading on Monday, reaching $143.66. 30,069 shares of the company were exchanged, compared to its average volume of 3,363,430. The company has a 50-day moving average of $138.09 and a two-hundred day moving average of $135.53. iShares Nasdaq Biotechnology ETF has a twelve month low of $92.15 and a twelve month high of $146.53.
Separately, ValuEngine cut iShares Nasdaq Biotechnology ETF from a “hold” rating to a “sell” rating in a research report on Monday, November 16th.
iShares Nasdaq Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.